| Brand name | Nonproprietary Name | Authorization date | Marketing authorisation holder |
|---|---|---|---|
| Nexviadyme | Avalglucosidase alfa | 2022-06-24 | Sanofi B.V. |
| Cabometyx | cabozantinib | 2016-09-09 | Ipsen Pharma |
| Cometriq | cabozantinib | 2014-03-21 | Ipsen Pharma |
| Bimervax | COVID-19 Vaccine (recombinant, adjuvanted) | 2023-03-30 | Hipra Human Health S.L. |
| Upstaza | eladocagene exuparvovec | 2022-07-18 | PTC Therapeutics International Limited |
| Vitrakvi | larotrectinib | 2019-09-19 | Bayer AG |
| Elonva | corifollitropin alfa | 2010-01-25 | N.V. Organon |
| Caelyx pegylated liposomal | doxorubicin | 1996-06-20 | Baxter Holding B.V. |
| RotaTeq | rotavirus vaccine, live | 2006-06-26 | Merck Sharp & Dohme B.V. |
| Dapagliflozin Viatris | dapagliflozin | 2023-03-24 | Viatris Limited |
| Orgalutran | ganirelix | 2000-05-16 | N.V. Organon |
| Briviact (in Italy: Nubriveo) | brivaracetam | 2016-01-13 | UCB Pharma SA |
| RoActemra | tocilizumab | 2009-01-15 | Roche Registration GmbH |
| Fuzeon | enfuvirtide | 2003-05-27 | Roche Registration GmbH |
| COVID-19 Vaccine (inactivated, adjuvanted) Valneva | COVID-19 vaccine (inactivated, adjuvanted, adsorbed) | 2022-06-24 | Valneva Austria GmbH |
| Thyrogen | thyrotropin alfa | 2000-03-09 | Sanofi B.V. |
| Skyrizi | risankizumab | 2019-04-26 | AbbVie Deutschland GmbH & Co. KG |
| Hepcludex | bulevirtide | 2020-07-31 | Gilead Sciences Ireland UC |
| Myozyme | alglucosidase alfa | 2006-03-28 | Sanofi B.V. |
| Tremelimumab AstraZeneca | tremelimumab | 2023-02-20 | AstraZeneca AB |